Damian Laber, MD

Provider

Damian Laber, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
MMG Satellite Oncology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Hematology
  • Medical Oncology
FELLOWSHIP:
  • UT MD Anderson Cancer Center - Hematology/Oncology
  • Baylor College of Medicine - Hematology/Oncology
RESIDENCY:
  • Huron Hospital, Cleveland Clinic Health Systems - Internal Medicine
  • Fred Hutchinson Cancer Research Center - Bone Marrow Transplant
MEDICAL SCHOOL:
  • University of Buenos Aires - MD
Provider

Damian Laber, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
MMG Satellite Oncology

Print Print Physician Bio

Publications

  • Sandoval-Sus JD, Mogollon-Duffo F, Patel A, Visweshwar N, Laber DA, Kim R, Jagal MV. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer. 2017 Jun;5:49. Pubmedid: 28642818. Pmcid: PMC5477132.
  • Visweshwar N, Jaglal M, Booth C, Griffin P, Laber D. AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia. Ann Hematol. 2016 Oct;95(10):1747-1749. Pubmedid: 27449072. Pmcid: PMC4982880.
  • Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014 Feb;32(1):178-187. Pubmedid: 24242861. Pmcid: PMC4560460.
  • Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. J Oncol. 2013 Jul;2009:567486. Pubmedid: 19424511. Pmcid: PMC2677718.
  • Storey RE, Huerta AL, Khan A, Laber DA. Spontaneous complete regression of hepatocellular carcinoma. Med Oncol. 2011 Dec;28(4):948-950. Pubmedid: 20467917.
  • Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA. Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck. Am J Med Sci. 2010 Feb;339(2):148-151. Pubmedid: 20087165.
  • Khan MI, Chesney JA, Laber DA, Miller DM. Digitalis, a targeted therapy for cancer?. Am J Med Sci. 2009 May;337(5):355-359. Pubmedid: 19440057.
  • Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009 Jun;86(3):151-164. Pubmedid: 19454272. Pmcid: PMC2716701.
  • Rezazadeh A, Laber DA, Ghim SJ, Jenson AB, Kloecker G. The role of human papilloma virus in lung cancer: a review of the evidence. Am J Med Sci. 2009 Jul;338(1):64-67. Pubmedid: 19593105.
  • Laber DA, Mushtaq M. Compassionate use of sorafenib in patients with advanced renal cell cancer. Clin Genitourin Cancer. 2009 Jan;7(1):34-38. Pubmedid: 19213666.
  • Jaglal MV, Laber DA, Arnold FW, Miller DM, Chesney JA, Kloecker GH. Obtaining routine blood cultures during interleukin-2-containing therapy is unnecessary. Am J Clin Oncol. 2009 Aug;32(4):429-431. Pubmedid: 19451801.
  • Rabinowits G, Laber DA. Bladder cancer: clinical practice. J Ky Med Assoc. 2009 Apr;107(4):129-133. Pubmedid: 19419018.
  • Slone SP, Martin AW, Wellhausen SR, Woods DR, Malone JC, Lear SC, Laber DA. IL-4 production by CD8+ lymphomatoid papulosis, type C, attracts background eosinophils. J Cutan Pathol. 2008 Oct;35 Suppl 1:38-45. Pubmedid: 18537857.
  • Cramer DE, Wagner S, Li B, Liu J, Hansen R, Reca R, Wu W, Surma EZ, Laber DA, Ratajczak MZ, Yan J. Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. Stem Cells. 2008 May;26(5):1231-1240. Pubmedid: 18339771.
  • Kloecker GH, Kannan CR, Laber DA, Rezazadeh A. Brain stem and clivus plasmacytoma. Am J Med Sci. 2008 Dec;336(6):503. Pubmedid: 19092324.
  • Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol. 2007 Oct;82(10):916-919. Pubmedid: 17597477.
  • Rabinowits G, Shuster TD, Pazianos AG, Laber DA. Indolent course of thymic carcinoid. J Clin Oncol. 2007 Mar;25(9):1138-1139. Pubmedid: 17369578.
  • Laber DA, Khan MI, Kloecker GH, Schonard C, Taft BS, Salvador C. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer Biol Ther. 2007 Jun;6(6):840-845. Pubmedid: 17582215.
  • Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol. 2007 Feb;78(2):161-166. Pubmedid: 17328717.
  • Choudry MA, Moffett BK, Laber DA. Pure red-cell aplasia secondary to pregnancy, characterization of a syndrome. Ann Hematol. 2007 Apr;86(4):233-237. Pubmedid: 17262194.
  • Laber DA, Okeke RI, Arce-Lara C, Taft BS, Schonard CL, McMasters KM, Kloecker GH, Miller DM. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J Cancer Res Clin Oncol. 2006 Sep;132(9):611-616. Pubmedid: 16741726.
  • Martin ME, Laber DA. Cefotetan-induced hemolytic anemia after perioperative prophylaxis. Am J Hematol. 2006 Mar;81(3):186-188. Pubmedid: 16493619.
  • Morgan JS, Laber DA. Ceftriaxone-resistant Salmonella septicemia and osteomyelitis in sickle cell disease adults. South Med J. 2006 Jun;99(6):625-627. Pubmedid: 16800421.
  • Laber DA, Goetz H K, Bhupalam L. Advances in the management of metastatic androgen-independent prostate cancer. J Ky Med Assoc. 2006 Feb;104(2):65-69. Pubmedid: 16594572.
  • Laber DA, Glisson SD, Hargis JB, Kosfeld RE, Goldsmith G, Cervera A, La Rocca RV. A phase II study of higher dose docetaxel in androgen-independent prostate cancer. Am J Clin Oncol. 2006 Aug;29(4):389-394. Pubmedid: 16891868.
  • Laber DA. Risk factors, classification, and staging of renal cell cancer. Med Oncol. 2006;23(4):443-454. Pubmedid: 17303902.
  • Laber DA, Martin ME. Etiology of thrombocytopenia in all patients treated with heparin products. Eur J Haematol. 2005 Aug;75(2):101-105. Pubmedid: 16000126.
  • Makoni SN, Laber DA. Clinical spectrum of myelophthisis in cancer patients. Am J Hematol. 2004 May;76(1):92-93. Pubmedid: 15114608.
  • Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004 Feb;100(4):859-868. Pubmedid: 14770445.
  • Laber DA. Why did he die?. Cancer Invest. 24(3):331-332. Pubmedid: 16809163.
  • Moffett PU, Moffett BK, Laber DA. Diagnosing and managing suspected malignant pleural effusions. J Support Oncol. 7(4):143-146. Pubmedid: 19731581.

Provider

Damian Laber, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
MMG Satellite Oncology

Print Print Physician Bio

Participating Trials

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Damian Laber, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
MMG Satellite Oncology

Print Print Physician Bio